Sarah Gordon Wild

Sarah Gordon Wild, Non-Executive Director: Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003 and has served on the Boards of Immunomedics and Praecis Pharmaceuticals. Previously, she was a Senior Biotechnology/Health Care Analyst for over 15 years at Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton. She currently serves as Non-Executive Director of Oxford Nanopore Technologies and Redx Pharma, Board Member of Lone Pine Capital LLC’s Offshore Funds and is a Partner and Board Member of Duke's Auctioneers in Dorset. She is a graduate from both Aberdeen University and Imperial College, University of London.